CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) and Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings.
Earnings and Valuation
This table compares CRISPR Therapeutics and Avalo Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CRISPR Therapeutics | $3.51 million | 1,360.55 | -$581.60 million | ($4.76) | -10.38 |
| Avalo Therapeutics | $60,000.00 | 6,194.26 | -$78.26 million | ($4.37) | -1.59 |
Avalo Therapeutics has lower revenue, but higher earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares CRISPR Therapeutics and Avalo Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CRISPR Therapeutics | -3,368.72% | -24.39% | -18.25% |
| Avalo Therapeutics | N/A | -58.03% | -48.22% |
Volatility and Risk
CRISPR Therapeutics has a beta of 1.76, suggesting that its share price is 76% more volatile than the S&P 500. Comparatively, Avalo Therapeutics has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for CRISPR Therapeutics and Avalo Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CRISPR Therapeutics | 1 | 7 | 9 | 2 | 2.63 |
| Avalo Therapeutics | 1 | 2 | 10 | 0 | 2.69 |
CRISPR Therapeutics currently has a consensus target price of $65.75, indicating a potential upside of 33.12%. Avalo Therapeutics has a consensus target price of $39.10, indicating a potential upside of 464.21%. Given Avalo Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Avalo Therapeutics is more favorable than CRISPR Therapeutics.
Institutional and Insider Ownership
69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are owned by institutional investors. 5.2% of CRISPR Therapeutics shares are owned by insiders. Comparatively, 4.5% of Avalo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Avalo Therapeutics beats CRISPR Therapeutics on 9 of the 15 factors compared between the two stocks.
About CRISPR Therapeutics
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
About Avalo Therapeutics
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
